Head-To-Head Contrast: Mural Oncology (MURA) versus The Competition

Mural Oncology (NASDAQ:MURA) is one of 1,049 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Mural Oncology to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Mural Oncology and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mural Oncology	0	0	3	1	3.25
Mural Oncology Competitors	7626	20915	48555	1194	2.55

Mural Oncology presently has a consensus price target of $16.00, suggesting a potential upside of 307.12%. As a group, “Pharmaceutical preparations” companies have a potential upside of 71.10%. Given Mural Oncology’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Mural Oncology is more favorable than its peers.

Institutional & Insider Ownership

80.2% of Mural Oncology shares are held by institutional investors. Comparatively, 44.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 0.1% of Mural Oncology shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Mural Oncology and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Mural Oncology	N/A	-$207.45 million	-0.43
Mural Oncology Competitors	$1.72 billion	$154.00 million	-5.60

Mural Oncology’s peers have higher revenue and earnings than Mural Oncology. Mural Oncology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Mural Oncology and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mural Oncology	N/A	-70.10%	-61.30%
Mural Oncology Competitors	-3,610.16%	-274.38%	-39.07%

Summary

Mural Oncology beats its peers on 8 of the 12 factors compared.

About Mural Oncology

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland.